Notably, as opposed to standard chemotherapy, a non-negligible percentage of BRAF-mutated cancer patients are benefitting from BRAF and/or MEK inhibitors and/or immunotherapy (anti-CTLA-4, -PD-1, -PD-L1) in terms of OS and tolerable toxicity. This evidence concerns the gene BRAF and cancer.